Healthcare provider profile · identity verified

Frederick K. Bulacan, M.D.

Internal Medicine · MENOMONEE FALLS, WI · NPI 1699768622

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1034	281
Amlodipine Besylate	Amlodipine Besylate	432	125
Losartan Potassium	Losartan Potassium	379	102
Lisinopril	Lisinopril	376	95
Pantoprazole Sodium	Pantoprazole Sodium	312	78
Omeprazole	Omeprazole	284	85
Levothyroxine Sodium	Levothyroxine Sodium	275	71
Gabapentin	Gabapentin	266	57
Metoprolol Succinate	Metoprolol Succinate	254	70
Metformin Hcl Er	Metformin Hcl	196	55
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	188	30
Albuterol Sulfate Hfa	Albuterol Sulfate	185	62
Furosemide	Furosemide	183	51
Rosuvastatin Calcium	Rosuvastatin Calcium	183	58
Hydrochlorothiazide	Hydrochlorothiazide	162	49
Oxycodone Hcl	Oxycodone Hcl	162	19
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	154	17
Metformin Hcl	Metformin Hcl	153	33
Tamsulosin Hcl	Tamsulosin Hcl	150	43
Metoprolol Tartrate	Metoprolol Tartrate	147	39
Simvastatin	Simvastatin	142	40
Eliquis	Apixaban	135	31
Allopurinol	Allopurinol	134	34
Alprazolam	Alprazolam	127	24
Jardiance	Empagliflozin	122	24
Zolpidem Tartrate	Zolpidem Tartrate	115	26
Sertraline Hcl	Sertraline Hcl	110	27
Tramadol Hcl	Tramadol Hcl	105	27
Clopidogrel	Clopidogrel Bisulfate	100	28
Duloxetine Hcl	Duloxetine Hcl	99	22
Tizanidine Hcl	Tizanidine Hcl	96	18
Warfarin Sodium	Warfarin Sodium	94	26
Fluticasone Propionate	Fluticasone Propionate	93	46
Pravastatin Sodium	Pravastatin Sodium	91	20
Ozempic	Semaglutide	90	13
Escitalopram Oxalate	Escitalopram Oxalate	82	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	74	19
Atenolol	Atenolol	72	20
Mounjaro	Tirzepatide	71	12
Glimepiride	Glimepiride	67	17
Mirtazapine	Mirtazapine	62	17
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	61	14
Trulicity	Dulaglutide	60	suppressed
Trazodone Hcl	Trazodone Hcl	59	13
Lorazepam	Lorazepam	57	12
Carvedilol	Carvedilol	52	13
Bupropion Xl	Bupropion Hcl	50	15
Ezetimibe	Ezetimibe	49	15
Donepezil Hcl	Donepezil Hcl	47	suppressed
Potassium Chloride	Potassium Chloride	47	15
Spironolactone	Spironolactone	47	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	46	14
Celecoxib	Celecoxib	43	12
Finasteride	Finasteride	41	12
Glipizide	Glipizide	41	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	39	12
Montelukast Sodium	Montelukast Sodium	38	suppressed
Benazepril Hcl	Benazepril Hcl	36	suppressed
Clonazepam	Clonazepam	36	12
Meloxicam	Meloxicam	36	13
Glipizide-Metformin	Glipizide/Metformin Hcl	34	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	34	suppressed
Diclofenac Sodium	Diclofenac Sodium	33	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	32	11
Lidocaine	Lidocaine	32	suppressed
Pregabalin	Pregabalin	31	suppressed
Colchicine	Colchicine	30	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	30	13
Ibuprofen	Ibuprofen	30	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	30	suppressed
Tresiba Flextouch U-100	Insulin Degludec	30	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Azithromycin	Azithromycin	29	24
Doxazosin Mesylate	Doxazosin Mesylate	29	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	29	suppressed
Buspirone Hcl	Buspirone Hcl	28	suppressed
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	28	suppressed
Diazepam	Diazepam	27	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	27	23
Symbicort	Budesonide/Formoterol Fumarate	27	suppressed
Famotidine	Famotidine	26	11
Humalog Kwikpen U-100	Insulin Lispro	26	suppressed
Levetiracetam	Levetiracetam	26	suppressed
Lovastatin	Lovastatin	26	suppressed
Torsemide	Torsemide	26	suppressed
Valsartan	Valsartan	26	suppressed
Breo Ellipta	Fluticasone/Vilanterol	24	suppressed
Citalopram Hbr	Citalopram Hydrobromide	23	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	23	12
Nitroglycerin	Nitroglycerin	23	13
Tradjenta	Linagliptin	23	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	22	suppressed
Lansoprazole	Lansoprazole	22	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	22	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	22	suppressed
Alendronate Sodium	Alendronate Sodium	21	suppressed
Bupropion Hcl Sr	Bupropion Hcl	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Bumetanide	Bumetanide	20	suppressed
Enalapril Maleate	Enalapril Maleate	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	18
Calcitriol	Calcitriol	18	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Irbesartan	Irbesartan	17	suppressed
Nifedipine Er	Nifedipine	17	suppressed
Prednisone	Prednisone	17	14
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	16	suppressed
Eszopiclone	Eszopiclone	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	16	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	14
Glipizide Er	Glipizide	15	suppressed
Myrbetriq	Mirabegron	15	suppressed
Naproxen	Naproxen	15	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	14	suppressed
Bupropion Hcl	Bupropion Hcl	14	suppressed
Cilostazol	Cilostazol	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	11
Pentoxifylline	Pentoxifylline	14	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Calcium Acetate	Calcium Acetate	13	suppressed
Creon	Lipase/Protease/Amylase	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Baclofen	Baclofen	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	12	suppressed
Doxepin Hcl	Doxepin Hcl	12	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Midodrine Hcl	Midodrine Hcl	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Risperidone	Risperidone	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error